Artificial Intelligence is rapidly transforming clinical research. From patient recruitment and protocol design to medical writing and data review, AI-powered solutions are becoming embedded across the clinical development lifecycle. More recently, the emergence of Agentic AI (systems capable of planning, reasoning, and executing multi-step workflows with varying degrees of autonomy) has generated significant excitement throughout the industry.

However, not all AI solutions are created equal. While many vendors promise dramatic improvements in efficiency and productivity, clinical trial organizations operate in one of the most highly regulated environments in the world. Success depends not only on technical performance but also on compliance, validation, governance, security, and trust.

As sponsors, CROs, and technology teams evaluate potential AI partners, they need a framework that extends beyond traditional software procurement criteria. The following considerations can help organizations assess both AI and Agentic AI vendors and identify solutions that are truly ready for clinical research.

1. Clinical Trial Domain Expertise

A common challenge when evaluating AI vendors is distinguishing between strong technology providers and true clinical research partners. Many companies possess impressive AI capabilities but lack a deep understanding of the complexities of clinical development.

Organizations should assess whether vendors have experience supporting functions such as protocol design, site selection, patient recruitment, eligibility screening, medical coding, safety monitoring, clinical operations, regulatory submissions, and clinical study report generation.

Beyond use cases, vendors should demonstrate familiarity with industry standards and regulations, including ICH-GCP, FDA and EMA guidance, CDISC standards, MedDRA, WHO Drug Dictionary, and common clinical technology ecosystems such as EDC, CTMS, and eCOA platforms.

Questions to ask include:

  • How many clinical trials has the solution supported?
  • Which therapeutic areas have been served?
  • Are there reference customers using the platform in production?
  • Has the solution demonstrated measurable outcomes or ROI?

2. AI and Agentic AI Capabilities

Technical capability remains a critical evaluation factor, but organizations should assess traditional AI and Agentic AI differently.

Evaluating Traditional AI

For conventional AI solutions, organizations should examine:

  • Accuracy and reliability
  • Precision and recall metrics
  • Hallucination rates
  • Benchmark performance
  • Retrieval-Augmented Generation (RAG) capabilities
  • Fine-tuning and model governance strategies

Understanding whether a vendor relies on proprietary models, commercial foundation models, or open-source technologies can also provide insight into scalability and long-term viability.

Evaluating Agentic AI

Agentic AI introduces a new set of evaluation criteria.

Unlike traditional AI systems that generate outputs in response to prompts, agentic systems can perform multi-step tasks, interact with enterprise applications, and make decisions within predefined boundaries.

Key areas to assess include:

  • Task planning and workflow decomposition
  • Multi-step reasoning capabilities
  • Dynamic decision-making
  • Integration with external systems
  • Tool and API utilization
  • Multi-agent orchestration
  • Autonomous versus human-supervised execution

Organizations should clearly understand which actions agents can perform independently and which require human review or approval.

Questions to ask include:

  • What percentage of workflows can be executed autonomously?
  • What safeguards exist to prevent unauthorized actions?
  • How are errors detected and handled?
  • How does the system escalate uncertainty to human users?

3. Regulatory Compliance, Validation, and Quality

In clinical research, regulatory readiness often matters more than cutting-edge technology.

Organizations should determine whether AI solutions can support regulated environments and comply with established validation practices. Vendors should demonstrate alignment with GxP requirements, FDA Computer Software Assurance (CSA) principles, and established validation methodologies.

Areas to evaluate include:

  • Validation documentation
  • Requirements traceability
  • Test evidence and execution records
  • Change control procedures
  • Release management processes
  • Model lifecycle management

Particular attention should be given to how vendors monitor and manage model drift, especially when machine learning models evolve over time.

Questions to ask include:

  • Has the platform been used in regulatory submissions?
  • Have regulatory agencies reviewed outputs generated by the system?
  • How is model performance monitored after deployment?
  • What documentation supports validation activities?

4. Security, Privacy, and Data Protection

Clinical trial data represents one of the most sensitive categories of information organizations manage. Any AI solution must meet stringent security and privacy requirements.

Organizations should review certifications and controls such as:

  • SOC 2 Type II
  • ISO 27001
  • HITRUST
  • Independent penetration testing

Compliance with privacy regulations should also be evaluated, including:

  • HIPAA
  • GDPR
  • UK GDPR
  • 21 CFR Part 11
  • Annex 11

AI-specific questions are equally important:

  • Is customer data used to train foundation models?
  • Are environments isolated by customer?
  • What are the data retention policies?
  • How are prompts and interactions logged and protected?

Understanding how vendors prevent data leakage and maintain customer isolation is particularly important when large language models are involved.

5. Governance, Explainability, and Human Oversight

Trust is essential when deploying AI in regulated environments.

Organizations should seek solutions that provide transparency into how outputs are generated and how decisions are made. This becomes even more critical with Agentic AI, where systems may perform actions rather than simply provide recommendations.

Strong governance frameworks should include:

  • Source attribution
  • Evidence traceability
  • Confidence scoring
  • Human approval workflows
  • Escalation mechanisms
  • Comprehensive audit trails

For agentic systems, organizations should also evaluate permission structures and action controls to ensure agents operate only within authorized boundaries.

An effective audit trail should capture:

  • Inputs and prompts
  • Retrieved source material
  • Generated outputs
  • User approvals
  • Agent actions
  • System decisions

6. Integration and Operational Readiness

Even the most capable AI solution can fail if it cannot integrate effectively into existing clinical operations.

Organizations should evaluate how easily the platform connects with existing technologies, including:

  • EDC platforms
  • CTMS solutions
  • eTMF systems
  • Safety systems
  • Data warehouses
  • Collaboration tools

API maturity, event-driven architecture, webhooks, and developer tooling are important indicators of operational readiness.

Deployment flexibility should also be assessed, including support for:

  • Multi-tenant SaaS
  • Dedicated cloud environments
  • Customer-managed cloud deployments
  • On-premises implementations

Scalability metrics such as study volume, document processing throughput, and response times should be reviewed to ensure the solution can support enterprise-wide adoption.

7. Vendor Stability and Strategic Partnership

The AI landscape is evolving rapidly, and many vendors are relatively young organizations.

Beyond evaluating the technology itself, organizations should assess the vendor's ability to support long-term clinical operations.

Key considerations include:

  • Financial stability
  • Funding and runway
  • Revenue growth
  • Customer retention
  • Product roadmap maturity
  • Support and service capabilities

Organizations should also determine whether the vendor provides access to clinical subject matter experts, implementation resources, and dedicated customer success teams.

A strong strategic partner should demonstrate not only technical innovation but also a commitment to supporting customers through evolving regulatory and operational requirements.

Additional Considerations for Agentic AI

As Agentic AI becomes more prevalent, organizations should incorporate several additional evaluation criteria into vendor assessments.

These include:

  • Levels of autonomy
  • Guardrails and policy enforcement
  • Agent memory management
  • Multi-agent coordination
  • Human escalation workflows
  • Hallucination mitigation strategies
  • Agent observability and monitoring
  • Failure recovery mechanisms
  • Agent testing frameworks
  • Agent version control and governance

Agentic AI should increasingly be viewed as a digital workforce. As a result, organizations must evaluate not only what agents can do but also how they are supervised, monitored, and controlled.

A Practical Scoring Framework

Many organizations find it useful to formalize evaluations using a weighted scorecard.

Category

Weight

Clinical Expertise

15%

AI & Agent Performance

20%

Regulatory & Validation

20%

Security & Privacy

15%

Governance & Explainability

10%

Integration & Operations

10%

Vendor Stability

10%

Minimum thresholds for consideration of a sponsor-grade deployment:

  • Regulatory/Validation: ≥ 16/20
  • Security/Privacy: ≥ 12/15
  • Explainability/Governance: ≥ 8/10
  • Overall score: ≥ 80/100

For regulated clinical trial environments, organizations may wish to establish minimum thresholds for critical areas such as validation, security, and governance before considering overall scores.

Conclusion

The promise of AI and Agentic AI in clinical research is substantial. These technologies have the potential to accelerate development timelines, reduce operational burden, improve data quality, and enable more efficient study execution.

Yet success will not be determined solely by model sophistication or autonomous capabilities. In clinical trials, the most valuable solutions are those that combine innovation with compliance, transparency, security, and operational maturity.

As Agentic AI evolves from an assistive technology to a digital workforce capable of taking action on behalf of users, organizations must evaluate vendors with the same rigor applied to any critical clinical process. Those who balance technological advancement with governance and regulatory readiness will be best positioned to realize the full potential of AI in clinical development.

‍